Mylan Laboratories’ Proposed Merger with King Pharmaceutical Harvard Case Solution & Analysis

Perry Capital possess shares in the King and, to facilitate the consent of the amalgamation, acquires shares in Mylan, whilst hedging out its economic exposure to the Mylan's share price utilizing derivatives. The price at which Mylan proposes to unify with King is generous to King investors, but the amalgamation does not look likely to be approved by Mylan shareholders, who must vote upon it. If Perry can swing the voting in favor of the deal, it will gain handsomely on its King shares without confronting any similar losses on its Mylan holdings since those are hedged. Another investor in Mylan, Carl Icahn, sued Perry for alleged vote buying and fought the price.

Mylan Laboratories' Proposed Merger with King Pharmaceutical Case Study Solution

PUBLICATION DATE: February 04, 2014 PRODUCT #: 214078-HCB-ENG

This is just an excerpt. This case is about FINANCE & ACCOUNTING

 

<iframe width="640" height="360" src="https://www.youtube.com/embed/_Iz0tCikZdU" frameborder="0" allowfullscreen></iframe>

Mylan Laboratories’ Proposed Merger with King Pharmaceutical Case Solution Other Similar Case Solutions like

Mylan Laboratories’ Proposed Merger with King Pharmaceutical

Share This